a New Front
in the War against Cancer
developing advanced therapies designed
to target and destroy the deadliest cancers
- melanoma, liver and breast - while
minimizing side effects
An Investigational Drug for Cancer
An Investigational Drug for Psoriasis and Atopic Dermatitis
Provectus presented at the BIO International Convention 2015 in Philadelphia on June 16, 2015 at 10:45 AM EDT.
A Melanoma News Today article reports on the comencement of enrollment for a phase 3 trial of PV-10 for locally advanced cutaneous melanoma.
A Melanoma News Today article reports on a presentation entitled "A Changing Topography: The Role of Intralesional Therapy in Melanoma" that was presented by Dr. Sanjiv Agarwala at ASCO 2015. In the presentation, Dr. Agarwala showed phase 2 findings for PV-10, showing the drug accumulated within cancer cells but not normal cells, inducing acute autophagy and exposing antigenic tumor fragments to antigenic presenting cells (APCs).
In an article appearing in Melanoma Management, Dr. Sanjib Agarwala discusses the potential clinical benefits of PV-10 for melanoma, stating "The promise suggested by the research to date is compelling - and if confirmed, translating these benefits to the clinic is a high priority."
Provectus presented at the Asia Biotech Invest Conference in Hong Kong on May 20, 2015 at 10:00 AM HKT.
A recent BioTuesday article discusses Provectus' novel approach of using physical chemistry and a different basis for the mechanism of action of its Rose Bengal based investigational anti-cancer agents, including PV-10, currently in phase 3 clinical testing.
Kate's Foundation created a news brief on last week's Modern Medicine/Dermatology Times article on treating metastatic melanoma with investigational drug PV-10.
An article appearing in Dermatology Times titled "Intralesional therapy for metastatic melanoma" discusses the "bystander" effect seen in clinical testing of intralesional PV-10 for melanoma and clinical evidence from studies at Moffitt Cancer Center that intralesional PV-10 induces a systemic immune response.
In support of Melanoma Awareness Month, an interview of Dr. Sanjiv Agarwala was aired on iHeart Radio 24/7 News on May 7, 2015.
Beginning May 4, 2015, an ad was aired on WAEB NewsRadio 790 in Allentown, PA informing the community that Provectus is seeking patients for the phase 3 trial of PV-10 for melanoma and that patients may now enrol at St. Luke's University Hospital and Health Network in Bethlehem, PA.
Audrey Adams recently interviewed Sanjiv Agarwala, MD on the syndicated radio program Talk With Audrey.
A DDN News article discusses the intralesional drug candidates, including PV-10, that are currently being investigated for advanced melanoma treatment.
Provectus will hold its quarterly business update conference call at 4 p.m. (EDT) May 7, 2015 to provide a business update on PV-10 and PH-10 to the investment community and answer questions from investors.
In recognition of National Melanoma Skin Cancer Prevention Month, Melanoma News Today reports on promising new strategies for the treatment of melanoma, including PV-10.
The Clinical News section of the April 27, 2015 edition of BioCentury included a clinical status update for Provectus reporting the initiation of a phase 3 trial of PV-10 for melanoma.
A Newswise article announces that Dr. Sanjiv Agarwala is available for media interview to discuss cutting-edge treatments that represent the recent surge in research aimed at battling late stage melanoma.
A BioPharm Insight article reports on Provectus efforts to partner with companies having PD1 or PDL1 inhibitor agents in late-stage development, noting the recently approved joint patent with Pfizer covering the use of PV-10 in combination with systemic inhibitors of immune system regulation.
Dermwire covers news that Provectus an Pfizer have received allowance from the FDA for a jointly held patent protecting the use of PV-10 in combination with systemic inhibitors of immune system regulation.
An audio recording of Provectus' panel discussion on Thursday, April 9, 2015 at The Harvard Club of New York City is now available.
Dermwire covers news that Provectus has opened enrollment of patients for its phase 3 international FDA comparative clinical trial of PV-10 for melanoma.
Provectus announced today that it has signed a Letter of Intent (the "LOI") with Boehringer Ingelheim (China) Investment Co. Ltd. ("Boehringer").
Provectus announced that data from its phase 1 study of PV-10 for chemoablation of hepatocellular carcinoma (HCC) and cancer metastatic to the liver was presented at the ESMO 17th World Congress on Gastrointestinal Cancer (ESMO-GI).
The American Association of Physicians of Indian Origin ("AAPI") honored Provectus Biopharmaceuticals, Inc. at a gala during the AAPI's 33rd Annual Convention and Scientific Assembly on Friday, June 19, 2015.
Provectus today announced that Dr. Vernon Sondak (Moffitt Cancer Center, Tampa, FL, USA) presented data on "Intralesional Therapy for Melanoma with PV-10" during the 5th European Post-Chicago Melanoma/Skin Cancer Meeting in Munich, Germany.
Provectus announced that its poster presentation titled "Trials in Progress: Intralesional Rose Bengal vs Systemic Chemotherapy for Treatment of Locally Advanced Cutaneous Melanoma" is on display at the 5th European Post-Chicago Melanoma / Skin Cancer Meeting in Munich, Germany.
Provectus announced that the abstract titled, "Phase 1 Study of PV-10 for Chemoablation of Hepatocellular Cancer and Cancer Metastatic to the Liver" to be presented at the ESMO 17th World Congress on Gastrointestinal Cancer is now available online at: http://annonc.oxfordjournals.org/content/26/suppl_4/iv33.1.full?sid=82267ebd-da5c-4a1a-9320-a795571b6085
Provectus announced today that it has completed its public offering of 17,500,000 shares of common stock and warrants to purchase 17,500,000 shares of common stock at a price to the public of $0.75 for a fixed combination of one share of common stock and a warrant to purchase one share of common stock.
Provectus announced that it has retained healthcare communications company PharmaHEALTHLabs to coordinate and facilitate an Investigator Advisory Board meeting to be held during 11th Brazilian Melanoma Conference from August 13-15, 2015 in Goiania, Brazil.
Provectus today announced the pricing of an underwritten public offering of 17,500,000 shares of common stock and warrants to purchase 17,500,000 shares of common stock with a public offering price of $0.75 for a fixed combination of one share of common stock and a warrant to purchase one share of common stock.
Provectus today announced that it intends to offer and sell shares of its common stock and warrants to purchase common stock, subject to market and other conditions, in an underwritten public offering. Provectus intends to use the net proceeds of the offering for clinical development, working capital and general corporate purposes.
Provectus announced that the Society of Surgical Oncology (SSO) has published an abstract describing preliminary research into use of the Company's investigational agent, PV-10, in murine models of colon cancer.
Provectus announced today that it will present at the 2015 BIO International Convention on Tuesday, June 16, at 10:45 am Eastern.
Provectus announced today that it has retained Allison+Partners as its new media relations consultant.
Provectus announced today that Dr. Sanjiv Agarwala, chief of medical oncology and hematology at St. Luke's Cancer Center in Bethlehem, Pennsylvania, and professor of medicine at Temple University School of Medicine in Philadelphia, presented data on PV-10 as an investigational intralesional treatment of melanoma at the 2015 American Society of Clinical Oncology's Annual Meeting on May 31, 2015.
Provectus announced today that the organizing committee of the 6th Asia-Pacific Primary Liver Cancer Expert Meeting has accepted the Company's abstract "Phase 1 Study of PV-10 for Chemoablation of Hepatocellular Cancer and Cancer Metastatic to the Liver", for a poster presentation.
Provectus today announced that the presentation committee of the 5th European Post-Chicago Melanoma / Skin Cancer Meeting has accepted its abstract titled "Trials in Progress: Intralesional Rose Bengal vs Systemic Chemotherapy for Treatment of Locally Advanced Cutaneous Melanoma."
Provectus today announced that it had extended for an additional 60 days its Memorandum of Understanding with with Sinopharm-China State Institute of Pharmaceutical Industry ("Sinopharm-CSIPI"), the leader among all pharmaceutical research institutes in China, and Sinopharm A-THINK Pharmaceutical Co., Ltd. ("Sinopharm A-THINK"), the only injectable anti-tumor drug research and development, manufacture and distribution integrated platform within Sinopharm Group.
Provectus announced today that the abstract titled, "Phase 1 Study of PV-10 for Chemoablation of Hepatocellular Cancer and Cancer Metastatic to the Liver," to be presented at the European Society for Medical Oncology's 17th World Congress on Gastrointestinal Cancer, is scheduled for Thursday, July 2, 2015 from 10:30 to 11:00 a.m. and 4:55 to 5:25 p.m. local time. Sanjiv S. Agarwala, MD, of St. Luke's University Hospital and Health Network, Bethlehem, PA, will be the presenter.
Provectus provided the market with a business update in its quarterly investor conference call held on Thursday, May 7, 2015, that addresses several matters in conjunction with the filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2015.
Provectus today announced its results of operations and financial condition for the first quarter ended March 31, 2015.
(c) 2002-2015 Provectus Biopharmaceuticals, Inc.
All rights reserved.
Artwork designed by Tracy E. Miller.